Risk factors and clinical characteristics at thromboembolic venous disease in young patients: A prospective study;Estudio prospectivo de los factores de riesgo y las características clínicas de la enfermedad tromboembólica en pacientes jóvenes

Medicina Clinica

Volumn 123, Issue 6, 2004, Pages 217-219

  García Fuster, María José ^a   Fernández, Conrado ^a   Forner, María José ^a   Vayá, Amparo ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antiphospholipid antibodies; Antithrombin; Factor V Leiden; Factor VIII; Hyperhomocisteinemia; PAI I; Protein C; Protein S; Prothrombin G20210A; Thromboembolic venous disease

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL DISORDER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; FAMILY HISTORY; FEMALE; HOSPITALIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; PREVALENCE; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTHROMBIN DEFICIENCY; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; VEIN DISEASE; VENOUS THROMBOEMBOLISM;

EID: 4243088034     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064421     Document Type: Article

References (10)

1. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1-6.
2. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001;86:395-403.
3. Briones A, Nauffal D, Villa P, Martínez MA, Menéndez R, Perpiñá M. Características clínicas y prevalencia de los estados de hipercoagulabilidad en pacientes con enfermedad tromboembólica venosa. Med Clin (Barc) 2001;116:201-5.
4. Mateo J, Oiiver A, Borrell M, Sala N, Fontcuberta J, the EMET Group. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost 1997;77:444-51.
5. Heijboer H, Brandjes DPM, Buller HR, Sturk A, Ten Cate LW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990;323:1512-6.
6. Tabernero MD, Tomas JF, Alberca I, Orfao A, López-Borrasca A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991;36:249-54.
7. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
8. Zanon E, Prandon P, Vianello F, Saggiorato G, Carraro G, Bagatell P, et al. Anti-beta 2-glycoprotein I antibodies in patientes with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res 1999;96:269-74.
9. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-34.
10. Seguí R, Estelles A, Mira Y, España F, Villa P, Falco C, et al. PAI-1 promoter 4G/5G genotipe as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 2000;111:122-8.